+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023 - Product Image

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4829015
  • Report
  • August 2019
  • Region: Global
  • 130 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • MORE
Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market: About this market

The HER2 inhibitors market analysis considers sales from both monotherapy and combination therapy. The analysis also considers the sales of HER2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the presence of blockbuster drugs and fewer side-effects will play a significant role in the monotherapy segment to maintain its market position. Also, the global HER2 inhibitors market report looks at factors such as the high prevalence of breast cancer and gastric cancer, recent approvals, and growing awareness about breast cancer. However, uncertainties in the introduction of Herceptin biosimilars, availability of alternative treatment options, and side effects of HER2 inhibitors may hamper the growth of the HER2 inhibitors industry over the forecast period.

Global HER2 Inhibitors Market: Overview

High prevalence of breast cancer and gastric cancer

HER2 regulates cell growth, survival, and differentiation through multiple signal transduction pathways. Owing to the overexpression of HER2, the prevalence of several cancers including breast cancer, gastric and ovarian cancer is increasing. As there is a significant unmet need for effective HER2 inhibitors with fewer side-effects, pharmaceutical companies have significant scope for growth. This will lead to the expansion of the global HER2 inhibitors market at a CAGR of almost 9% during the forecast period.

Patient assistance programs

HER2 inhibitors are available at high costs, making it difficult for patients to purchase them. Thus, pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden, thus increasing patient adherence to HER2 inhibitors. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global HER2 inhibitors market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 inhibitors manufacturers, that include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc.

Also, the HER2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Monotherapy - Market size and forecast 2018-2023
  • Combination therapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Patient assistance programs
  • Introduction of new diagnostics for breast cancer
  • Strategic alliances
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Blockbuster drug sales for last three years
Exhibit 22: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Sales of PERJETA for last three years
Exhibit 25: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Effect on Herceptin sales after launch of biosimilars
Exhibit 45: Examples of available Herceptin biosimilars
Exhibit 46: Side effects associated with HER2 inhibitors
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Approximate cost of HER2 inhibitors
Exhibit 49: Examples of recently approved diagnostics for breast cancer
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 56: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 57: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 58: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 59: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 60: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 61: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 62: Merck & Co. Inc. - Vendor overview
Exhibit 63: Merck & Co. Inc. - Business segments
Exhibit 64: Merck & Co. Inc. - Organizational developments
Exhibit 65: Merck & Co. Inc. - Geographic focus
Exhibit 66: Merck & Co. Inc. - Segment focus
Exhibit 67: Merck & Co. Inc. - Key offerings
Exhibit 68: Merck & Co. Inc. - Key customers
Exhibit 69: Novartis AG - Vendor overview
Exhibit 70: Novartis AG - Business segments
Exhibit 71: Novartis AG - Organizational developments
Exhibit 72: Novartis AG - Geographic focus
Exhibit 73: Novartis AG - Segment focus
Exhibit 74: Novartis AG - Key offerings
Exhibit 75: Novartis AG - Key customers
Exhibit 76: Pfizer Inc. - Vendor overview
Exhibit 77: Pfizer Inc. - Business segments
Exhibit 78: Pfizer Inc. - Organizational developments
Exhibit 79: Pfizer Inc. - Geographic focus
Exhibit 80: Pfizer Inc. - Segment focus
Exhibit 81: Pfizer Inc. - Key offerings
Exhibit 82: Pfizer Inc. - Key customers
Exhibit 83: Puma Biotechnology Inc. - Vendor overview
Exhibit 84: Puma Biotechnology Inc. - Business segments
Exhibit 85: Puma Biotechnology Inc. - Organizational developments
Exhibit 86: Puma Biotechnology Inc. - Key offerings
Exhibit 87: Puma Biotechnology Inc. - Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • MORE
The following companies are recognised as the key players in the global HER2 inhibitors market: F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is patient assistance programs.”

According to the report, one of the major drivers for this market is the high prevalence of breast cancer and gastric cancer.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of HER2 inhibitors.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll